While the almost 70% price reduction in important tuberculosis prevention drug Rifapentine for 100 countries with significant TB epidemics is a breakthrough, the high cost of newer drugs remains a barrier.
At a recent international TB conference, some doctors suggested countries with weak health systems should not be allowed to use new TB drugs, although the old ones are ineffectual and cause deafness. Thankfully, South Africa is leading the world in treating drug-resistant TB.
Concerns around the efficacy of the drug Nevirapine in preventing mother-to-child transmission of HIV causes delays in provinces responding to an October 1 deadline for identifying their own sites for testing. KERRY CULLINAN reports.